226 related articles for article (PubMed ID: 33119972)
1. Kinetic profile of N,N-dimethyltryptamine and β-carbolines in saliva and serum after oral administration of ayahuasca in a religious context.
Lanaro R; Mello SM; da Cunha KF; Silveira G; Corrêa-Neto NF; Hyslop S; Cabrices OG; Costa JL; Linardi A
Drug Test Anal; 2021 Mar; 13(3):664-678. PubMed ID: 33119972
[TBL] [Abstract][Full Text] [Related]
2. Monoamine oxidase inhibitors in South American hallucinogenic plants: tryptamine and beta-carboline constituents of ayahuasca.
McKenna DJ; Towers GH; Abbott F
J Ethnopharmacol; 1984 Apr; 10(2):195-223. PubMed ID: 6587171
[TBL] [Abstract][Full Text] [Related]
3. Metabolism and disposition of N,N-dimethyltryptamine and harmala alkaloids after oral administration of ayahuasca.
Riba J; McIlhenny EH; Valle M; Bouso JC; Barker SA
Drug Test Anal; 2012; 4(7-8):610-6. PubMed ID: 22514127
[TBL] [Abstract][Full Text] [Related]
4. Gas chromatographic analysis of dimethyltryptamine and beta-carboline alkaloids in ayahuasca, an Amazonian psychoactive plant beverage.
Pires AP; De Oliveira CD; Moura S; Dörr FA; Silva WA; Yonamine M
Phytochem Anal; 2009; 20(2):149-53. PubMed ID: 19140116
[TBL] [Abstract][Full Text] [Related]
5. Identification of N,N-dimethyltryptamine and beta-carbolines in psychotropic ayahuasca beverage.
Gambelunghe C; Aroni K; Rossi R; Moretti L; Bacci M
Biomed Chromatogr; 2008 Oct; 22(10):1056-9. PubMed ID: 18506697
[TBL] [Abstract][Full Text] [Related]
6. Mutagenicity of Ayahuasca and Their Constituents to the Salmonella/Microsome Assay.
Kummrow F; Maselli BS; Lanaro R; Costa JL; Umbuzeiro GA; Linardi A
Environ Mol Mutagen; 2019 Apr; 60(3):269-276. PubMed ID: 30488498
[TBL] [Abstract][Full Text] [Related]
7. Determination of N,N-dimethyltryptamine and beta-carboline alkaloids in human plasma following oral administration of Ayahuasca.
Yritia M; Riba J; Ortuño J; Ramirez A; Castillo A; Alfaro Y; de la Torre R; Barbanoj MJ
J Chromatogr B Analyt Technol Biomed Life Sci; 2002 Nov; 779(2):271-81. PubMed ID: 12361741
[TBL] [Abstract][Full Text] [Related]
8. A rapid analytical strategy for the determination of ayahuasca alkaloids in non-ritualistic approaches by UHPLC-MS/MS.
Eller S; Borges GR; Ossanes DS; Birk L; Scheid C; Yonamine M; Grossi P; Merib JO; Oliveira TF
Forensic Sci Int; 2020 Jul; 312():110298. PubMed ID: 32387868
[TBL] [Abstract][Full Text] [Related]
9. Effect of Ritualistic Consumption of Ayahuasca on Hepatic Function in Chronic Users.
Mello SM; Soubhia PC; Silveira G; Corrêa-Neto NF; Lanaro R; Costa JL; Linardi A
J Psychoactive Drugs; 2019; 51(1):3-11. PubMed ID: 30582439
[TBL] [Abstract][Full Text] [Related]
10. Ritualistic Use of Ayahuasca versus Street Use of Similar Substances Seized by the Police: A Key Factor Involved in the Potential for Intoxications and Overdose?
Lanaro R; Calemi DB; Togni LR; Costa JL; Yonamine M; Cazenave Sde O; Linardi A
J Psychoactive Drugs; 2015; 47(2):132-9. PubMed ID: 25950593
[TBL] [Abstract][Full Text] [Related]
11. Determination of Tryptamines and β-Carbolines in Ayahuasca Beverage Consumed During Brazilian Religious Ceremonies.
Santos MC; Navickiene S; Gaujac A
J AOAC Int; 2017 May; 100(3):820-824. PubMed ID: 28105971
[TBL] [Abstract][Full Text] [Related]
12. Human pharmacology of ayahuasca: subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics.
Riba J; Valle M; Urbano G; Yritia M; Morte A; Barbanoj MJ
J Pharmacol Exp Ther; 2003 Jul; 306(1):73-83. PubMed ID: 12660312
[TBL] [Abstract][Full Text] [Related]
13. Investigation of Ayahuasca β-Carboline Alkaloids and Tryptamine in Sweat Samples from Religious Community Participants by GC-MS.
Tavares L; Monedeiro F; Bordin DM; De Martinis BS
J Anal Toxicol; 2020 Jul; 44(6):601-609. PubMed ID: 32103256
[TBL] [Abstract][Full Text] [Related]
14. Biodiversity of β-Carboline Profile of
Santos BWL; Oliveira RC; Sonsin-Oliveira J; Fagg CW; Barbosa JBF; Caldas ED
Plants (Basel); 2020 Jul; 9(7):. PubMed ID: 32660098
[TBL] [Abstract][Full Text] [Related]
15. Autonomic, neuroendocrine, and immunological effects of ayahuasca: a comparative study with d-amphetamine.
Dos Santos RG; Valle M; Bouso JC; Nomdedéu JF; Rodríguez-Espinosa J; McIlhenny EH; Barker SA; Barbanoj MJ; Riba J
J Clin Psychopharmacol; 2011 Dec; 31(6):717-26. PubMed ID: 22005052
[TBL] [Abstract][Full Text] [Related]
16. Immunological Modulation and Control of Parasitaemia by Ayahuasca Compounds: Therapeutic Potential for Chagas's Disease.
Katchborian-Neto A; Santos MFC; Vilas-Boas DF; Dos Santos EG; Veloso MP; Bueno PCP; Caldas IS; Soares MG; Dias DF; Chagas-Paula DA
Chem Biodivers; 2022 Oct; 19(10):e202200409. PubMed ID: 36163588
[TBL] [Abstract][Full Text] [Related]
17. Neuroprotective potential of Ayahuasca and untargeted metabolomics analyses: applicability to Parkinson's disease.
Katchborian-Neto A; Santos WT; Nicácio KJ; Corrêa JOA; Murgu M; Martins TMM; Gomes DA; Goes AM; Soares MG; Dias DF; Chagas-Paula DA; Paula ACC
J Ethnopharmacol; 2020 Jun; 255():112743. PubMed ID: 32171895
[TBL] [Abstract][Full Text] [Related]
18. Ayahuasca: Psychological and Physiologic Effects, Pharmacology and Potential Uses in Addiction and Mental Illness.
Hamill J; Hallak J; Dursun SM; Baker G
Curr Neuropharmacol; 2019; 17(2):108-128. PubMed ID: 29366418
[TBL] [Abstract][Full Text] [Related]
19. Various alkaloid profiles in decoctions of Banisteriopsis caapi.
Callaway JC
J Psychoactive Drugs; 2005 Jun; 37(2):151-5. PubMed ID: 16149328
[TBL] [Abstract][Full Text] [Related]
20. Ayahuasca Exposure: Descriptive Analysis of Calls to US Poison Control Centers from 2005 to 2015.
Heise CW; Brooks DE
J Med Toxicol; 2017 Sep; 13(3):245-248. PubMed ID: 27896660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
